Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Ono seeks Japanese approval for Opdivo for head and neck cancer

July 29, 2016

Tesaro initiates phase I study of TSR-022 for advanced solid tumors

July 29, 2016

EMA grants PRIME designation to DNX-2401 for recurrent glioblastoma

July 28, 2016

Janssen, BMS enter immuno-oncology collaboration in lung cancer

July 28, 2016

NY-ESO SPEAR T-cell therapy receives orphan drug designation in the E.U.

July 27, 2016

AbbVie and BMS to evaluate Rova-T with checkpoint inhibitors for SCLC

July 26, 2016

FDA grants new breakthrough therapy designation to Darzalex in multiple myeloma

July 26, 2016

XBiotech reports progress for Xilonix in U.S. and E.U.

July 25, 2016

Amgen and Allergan report phase III results for ABP-980

July 22, 2016

FDA gives fast track status to axalimogene filolisbac

July 22, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...